Mol2Med™ First-Time-Right Approach - Crystal Pharmatech Co., Ltd.

In this series, we will discuss how it is possible to accelerate from Candidate Selection to Phase I FIH cost effectively, within 12 months, and with visibility into future clinical trials. A recent survey of 150 biopharmaceutical development scientists concludes:

Formulation issues have led to project failure and significant delays for about 60% of responding companies.
Of those projects, a delay of more than 12 months was reported by 52%
10% experienced complete failure

This study's findings highlight the importance of first-time-right development to avoid costly delays.

Mol2Med™ First-Time-Right Approach

Setting the Stage for Clinical Success: Formulating Small Molecules Right from the Beginning

Speaker: Dr. Feng Li, Chief Scientific Officer of CDMO Business Unit, Crystal Pharmatech

Date: 2:00-3:00 pm EDT, Wednesday, Watch on-demand



Mol2Med™ First-Time-Right Approach

Crystal Form Screening and Selection: Paving the Way to Successful Development

Speaker: Dr. Rosi Petrova, Head of US Small Molecule Division, Crystal Pharmatech

Date: 2:00-3:00 pm EDT, Wednesday, Whatch on-demand



Mol2Med™ First-Time-Right Approach

Developability Assessment of Small Molecule Lead/PCC to Select Best Development Path Forward

Speaker: Dr. Bob Wenslow, Co-founder and Vice President of Business Development, Crystal Pharmatech

Date: 2:00-3:00 pm EDT, Wednesday, Watch on-demand



Mol2Med™ First-Time-Right Approach

Mol2Med™ Program: 3-Step, First-Time-Right Approach to Move PCC to FIH

Speaker: Dr. Bob Wenslow, Co-founder and Vice President of Business Development, Crystal Pharmatech

Date: 2:00-3:00 pm EDT, Wednesday, Watch on-demand



Small Molecule

First-Time-Right 3-STEP Approach Developability Assessment API Form and Solid-State Research Crystallization Development Services Pre-formulation Studies Analytical Research and Quality Control Formulation Development Clinical and Commercial GMP Manufacturing Clinical Supply

Crystal Bio Solutions

Biologics Characterization and CMC Analytics Bioanalytical and Biomarker Services Quantitative Clinical Pharmacology (QCP)

Crystal NAX

DNA Synthesis RNA Synthesis LNP Formulation Services Analytical & Characterization Services Early-Phase Manufacturing Catalogue Products

Platforms

Solid Form Screening Solid Form Developability Evaluation Absolute Structure Determination Crystallization Process Development Conventional Oral Solid Dosage Forms Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides Mini-tablet

Quick Links

Highlights News Events Knowledge Hub Webinar Series

 bd_global@crystalpharmatech.com  (925) 558-5040



U.S
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512

2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512

CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566

Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1

China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China 215123

Floor 1, Bldg. 3, 68 Chunpu Road, Suzhou Industrial Park, Suzhou, China 215123

Subscribe to be the first to get the updates!

Sitemap